Pravastatin: Nursing Drug Guide, Myopathy & Hold Rules
Pravastatin lowers LDL and reduces cardiovascular risk in high blood cholesterol, but nursing safety centers on myopathy and rhabdomyolysis recognition. Before every dose, screen for unexplained muscle pain, muscle weakness, or dark urine—especially with cyclosporine, colchicine, or niacin on the MAR. Hold and escalate early to limit progression to acute kidney injury.
Pravastatin can cause myopathy and rhabdomyolysis. Risk rises with gemfibrozil (avoid), cyclosporine (max 20 mg/day), colchicine, niacin, other fibrates, and higher daily doses. Labeling defines myopathy with CK above ten times the upper limit of normal. Hold immediately when unexplained muscle pain, tenderness, weakness, or dark urine appears—do not wait for the next scheduled lab draw.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before each dose, ask about new muscle symptoms and verify cyclosporine dose limits (max 20 mg), gemfibrozil avoidance, and colchicine/niacin combinations. Pravastatin has minimal grapefruit effect compared with CYP3A4-sensitive statins—focus surveillance on muscle cues and interaction dose caps.
Most common brand names
Pravastatin is the generic name used in medication orders.
Common brand: Pravachol. Tablets are supplied as 10 mg, 20 mg, 40 mg, and 80 mg in many products—confirm strength before administration.
Why we give it — Indications
Pravastatin reduces LDL cholesterol and cardiovascular risk in adults with primary hyperlipidemia, selected prevention populations, and pediatric heterozygous familial hypercholesterolemia (HeFH) age 8 years and older.
| Use | Nursing relevance |
|---|---|
| Primary hyperlipidemia | Used with diet and risk-factor control to lower LDL and non-HDL cholesterol |
| ASCVD risk reduction | Reduces recurrent event risk in people with established atherosclerosis, prior heart attack, stroke, or angina |
| Diabetes risk profile | Often prescribed in adults with type 2 diabetes and additional cardiovascular risk factors |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Pravastatin is an active HMG-CoA reductase inhibitor that lowers hepatic cholesterol synthesis and upregulates LDL receptors. Unlike lovastatin and simvastatin, pravastatin is not a CYP3A4 substrate and has minimal grapefruit juice interaction per labeling. Track response on lipid panel trends and safety through muscle symptoms, CK, and liver enzymes.
Dosing overview
Per DailyMed, give pravastatin orally once daily at any time of day, with or without food. The recommended adult starting dosage is 40 to 80 mg once daily. For patients who need high-intensity statin therapy or cannot reach LDL goals on 80 mg daily, consider alternative LDL-lowering treatment per labeling.
Pharmacokinetics
Pravastatin is administered in the active form. Food reduces AUC and Cmax but lipid-lowering effects are similar with or without meals per DailyMed.
| Parameter | Value (DailyMed) | Nursing relevance |
|---|---|---|
| Peak concentration (Tmax) | 1 to 1.5 hours after oral dose | Rapid absorption; timing relative to meals is flexible |
| Onset of absorption | Peak by ~1.5 hours; bioavailability ~17% | Cholesterol lowering is a chronic effect—adherence matters more than clock time |
| Elimination half-life (pravastatin) | ~1.8 hours | Short parent half-life; once-daily dosing reflects hepatic effect duration |
| Total radioactivity half-life | ~77 hours (drug plus metabolites) | Metabolites persist longer; muscle toxicity surveillance continues across doses |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review baseline cardiovascular indication and current lipid goals
- Check baseline hepatic panel and symptom history for prior statin intolerance
- Screen MAR for gemfibrozil (avoid), cyclosporine (max 20 mg pravastatin), colchicine, and niacin
- Verify pravastatin dose does not exceed interaction limits (cyclosporine 20 mg; macrolides 40 mg)
- Screen for untreated contributors to statin myopathy risk such as hypothyroidism
- Ask about new muscle symptoms at every contact in high-risk patients
Contraindications (DailyMed)
- Hypersensitivity to pravastatin or any excipient in the formulation
- Acute liver failure or decompensated cirrhosis
Pregnancy and lactation are not listed as contraindications in section 4 of the reviewed label, but labeling advises discontinuing pravastatin when pregnancy is recognized and that breastfeeding is not recommended during therapy.
Important interactions
| Drug / factor | Risk | Nursing action |
|---|---|---|
| Gemfibrozil | Increased myopathy/rhabdomyolysis risk | Avoid concomitant use per labeling; hold and notify if ordered together |
| Cyclosporine | Markedly increased myopathy risk; raises pravastatin exposure | Verify dose ≤20 mg daily; hold if ordered above limit without clearance |
| Clarithromycin / erythromycin | Increased pravastatin exposure | Do not exceed 40 mg pravastatin once daily |
| Niacin | Additive myopathy risk | Increase symptom surveillance; escalate new muscle complaints promptly |
| Other fibrates | Additive myopathy risk | Monitor closely during initiation and dose titration |
| Colchicine | Myopathy including rhabdomyolysis reported | Use caution; hold for muscle symptoms and coordinate renal monitoring |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet given once daily at any time of day, with or without food. Lipid-lowering effects are similar whether taken with meals or one hour before meals per DailyMed.
- Verify tablet strength (10 mg, 20 mg, 40 mg, or 80 mg) before administration
- Complete medication reconciliation at admission—avoid duplicate statin therapy
- Confirm thyroid status; untreated hypothyroidism increases myopathy susceptibility
- Pravastatin has minimal grapefruit juice effect compared with CYP3A4-sensitive statins—still verify all new co-medications with pharmacy
Discontinue pravastatin when pregnancy is recognized. Statins may cause fetal harm based on mechanism of action. Breastfeeding is not recommended during pravastatin therapy. Counsel women of childbearing potential about effective contraception when pravastatin is prescribed.
Expected therapeutic response
- LDL reduction and improved non-HDL profile at follow-up lipid testing
- Long-term reduction in recurrent cardiovascular events in indicated populations
- Stable liver and kidney trend data without progressive toxicity signs
- No new muscle complaints requiring interruption
Red flags — Stop and act
Pause dose and escalate promptly when symptoms suggest severe statin toxicity or major hepatic injury.
- Rapidly worsening diffuse myalgia with weakness, especially with dark urine or oliguria
- Severe fatigue with unexplained CK rise and creatinine increase
- New scleral icterus or skin yellowing compatible with jaundice
- Pravastatin dose above cyclosporine limit (20 mg) without prescriber clearance
Adverse effects
| Adverse effect | Clinical context | Nursing response |
|---|---|---|
| Myalgia / mild myopathy | Most frequent muscle-related complaint | Assess severity and pattern; review interactions and thyroid status; escalate if worsening |
| Rhabdomyolysis | Rare but high severity; may include renal injury | Hold dose, urgent prescriber/pharmacy notification, trend CK and renal markers |
| Transaminase elevation | May occur early or after dose changes | Trend labs and symptoms; report sustained elevations with symptoms |
| GI symptoms | Dyspepsia or nausea can occur | Support symptom control while ruling out liver injury when persistent |
| Hyperglycemia trend | Possible class effect in susceptible groups | Coordinate periodic glucose/HbA1c review with chronic disease plan |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Accidental ingestions have been reported without specific symptoms and with full recovery in labeling. No specific treatment of pravastatin overdosage is recommended until further experience is obtained.
Labeling guidance
- No specific treatment of pravastatin overdosage is recommended in the reviewed prescribing information
- Use supportive, symptom-directed care and monitor for muscle and hepatic injury patterns
- Contact poison control or medical toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Pravastatin vs simvastatin vs lovastatin — similar names; verify intended agent and interaction dose limits
- Pravastatin vs atorvastatin/rosuvastatin — different potency and interaction profiles; do not substitute without prescriber order
- Cyclosporine dose-cap errors — pravastatin 40 mg ordered with cyclosporine exceeds the 20 mg maximum
- Strength mix-ups — confirm 10 mg, 20 mg, 40 mg, or 80 mg tablet before administration
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Muscle symptom interview | Ask location, onset, severity, and progression each shift in symptomatic or high-risk patients |
| Interaction check | Confirm cyclosporine dose cap (max 20 mg), gemfibrozil avoidance, and colchicine/niacin combinations after transfers |
| Renal warning signs | Track urine color and output when muscle injury is suspected |
| Hepatic warning signs | Pair symptom interview with trend review of transaminases and bilirubin |
| Dose verification | Flag pravastatin doses above interaction limits before administration |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults and frail patients | Higher symptom-report barriers; schedule proactive checks rather than waiting for complaints |
| Polypharmacy with cyclosporine or colchicine | Higher myopathy risk; verify dose caps at every MAR review |
| Renal impairment | Myopathy risk factor; start 10 mg in severe renal impairment (max 40 mg) |
| Endocrine comorbidity | Uncontrolled hypothyroidism increases myopathy susceptibility |
| Pregnancy or planned conception | Contraindicated—discontinue immediately when pregnancy is recognized |
| Lactation | Not recommended—breastfeeding should be avoided during maternal pravastatin therapy |
| Age ≥65 years | Predisposing factor for myopathy; use caution and proactive symptom checks |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Serial symptom screen for myalgia, weakness, cramps, and functional decline
- Lipid response and adherence trends; coordinate HbA1c plans where diabetes risk is high
- Hepatic trends including ALT and AST when clinically indicated
- Renal and metabolic trends when rhabdomyolysis is suspected
| Priority lab | Use in pravastatin safety workflow |
|---|---|
| ALT | Investigate hepatocellular injury when symptoms or transaminase rise appears |
| AST | Trend with ALT for hepatic signal consistency |
| Basic metabolic panel | Tracks creatinine/electrolyte impact when rhabdomyolysis concern exists |
| HbA1c | Supports long-term cardiometabolic risk review |
On a small screen, swipe or scroll sideways to see the full table.
Document
- Exact symptom wording and onset relative to dose timing
- Interaction review performed before administration
- Hold actions and provider-pharmacist notifications
- Follow-up plans and patient teach-back for muscle symptom reporting
- Interaction dose-cap verification documented in clinical documentation
Patient teaching
- Take pravastatin once daily at any time— with or without food— at about the same time each day
- Report unexplained muscle pain, tenderness, weakness, fever, or dark urine immediately—do not wait for the next visit
- Tell clinicians about every new medicine, including transplant drugs and gout therapy, before the next dose
- Stop pravastatin and contact the care team immediately if pregnancy is recognized; do not breastfeed during therapy
- Pravastatin has less grapefruit interaction than some other statins, but always confirm new supplements with your pharmacist
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Myopathy is diagnosed or suspected, or CK is markedly elevated
- New unexplained muscle pain, tenderness, or weakness—especially with dark urine
- Pravastatin dose exceeds cyclosporine limit (20 mg) or macrolide limit (40 mg) without clearance
- Gemfibrozil appears on the MAR (avoid combination per labeling)
- Acute liver failure, decompensated cirrhosis, serious hepatic injury with jaundice, or hypersensitivity is present
- Pregnancy is recognized or patient is breastfeeding
- Acute serious illness predisposing to rhabdomyolysis-related renal failure until team reviews continuation
Hold parameters can vary by institution. Follow prescriber orders, pharmacy guidance, and local policy.
Clinical practice integration and workflow
Pravastatin errors often involve missed cyclosporine dose-cap checks, undisclosed colchicine combinations, or delayed response to early muscle symptoms. Build a workflow that pairs MAR review with brief symptom screening before each dose.
1. Check-before-you-give protocol
- Verify right drug, strength, and schedule against current indication
- Ask focused muscle-symptom question before dose
- Screen medication updates for cyclosporine, gemfibrozil, colchicine, and niacin risk
- Review latest liver, renal, and CK trend data if symptoms are present
2. High-alert and safety badge
Rhabdomyolysis risk — symptom-driven hold and escalationPravastatin is often well tolerated, but cyclosporine co-therapy or doses above interaction limits can convert a routine statin dose into a high myopathy risk. Treat new proximal pain or dark urine as a hold-and-escalate event.
3. Clinical workflow: hold and question rules
- If muscle symptoms appear after a medication change, hold and trigger interaction review before next dose
- If CK and creatinine rise together, escalate for rhabdomyolysis pathway and supportive management
- If pravastatin exceeds cyclosporine dose cap, hold and notify prescriber/pharmacist same day
4. Critical teach-back questions
- “What symptoms mean you should call us before the next dose?” (Patient should include severe muscle pain, weakness, and dark urine.)
- “What new medicines should you report before your next pravastatin dose?” (Patient should include transplant drugs, gout therapy, and any new lipid medicines.)
5. Care coordination
Pharmacist: Interaction stratification, dose optimization, and escalation thresholds for muscle toxicity
Prescriber / cardiology / primary team: Ongoing lipid strategy, adverse event decision-making, and post-hold rechallenge planning
🧠 Quick mental checklist
- Any new proximal pain, weakness, or reduced activity tolerance today?
- Any change in urine color, urine output, or creatinine trend?
- Any newly added cyclosporine, colchicine, niacin, or fibrate since the last administration?
- Is pravastatin dose within cyclosporine limit (≤20 mg) if applicable?
- Are hold criteria clearly documented and understood by patient and team?
Pravastatin NCLEX practice questions
Use this NCLEX-style clinical judgment practice set for pravastatin after reviewing the tabbed case panel (MAR, labs, history, nursing notes). Items include priority action, SATA cue recognition, trend interpretation, matrix urgency judgment, flexible administration timing, and overdose documentation—focused on myopathy recognition and cyclosporine dose limits.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Pravastatin 40 mg PO once daily (2100)
- Cyclosporine 150 mg PO twice daily
- Colchicine 0.6 mg PO twice daily (gout prophylaxis)
- Prednisone 5 mg PO daily
- Amlodipine 5 mg PO daily
- Day 0: CK 95 U/L, creatinine 1.0 mg/dL, LDL 142 mg/dL
- Day 7: CK 210 U/L, creatinine 1.1 mg/dL
- Day 14: CK 680 U/L, creatinine 1.4 mg/dL, AST 62 U/L, ALT 58 U/L
- Urinalysis today: large blood on dipstick, few RBCs on microscopy
- 52-year-old kidney transplant recipient; hyperlipidemia since transplant
- Pravastatin started at 40 mg at outside clinic—no pharmacy interaction check documented
- History of gout; colchicine added day 10
- Renal function baseline creatinine 1.0 mg/dL; not on dialysis
- Reports diffuse thigh and shoulder aching worsening over 48 hours
- Urine “cola-colored” since yesterday; denies chest pain or shortness of breath
- Evening pravastatin dose due at 2100
- Pharmacy message pending on cyclosporine–statin dose cap
Answer key & rationale
Frequently asked questions
Why is myopathy the main nursing safety concern with pravastatin?
Pravastatin can cause myopathy and rhabdomyolysis. Risk rises with gemfibrozil, cyclosporine, colchicine, niacin, and higher doses. Hold for unexplained muscle pain, tenderness, weakness, or dark urine.
What is the maximum pravastatin dose with cyclosporine?
DailyMed limits pravastatin to 10 mg starting dose and a maximum of 20 mg once daily when cyclosporine is co-prescribed.
What should patients do if pregnancy is recognized while taking pravastatin?
Discontinue pravastatin immediately. Statins may cause fetal harm based on mechanism of action. Breastfeeding is not recommended during therapy.
How should pravastatin be taken?
Give orally once daily at any time of day, with or without food. Lipid-lowering effects are similar whether taken with meals or one hour before meals.
Is there an antidote for pravastatin overdose?
No specific treatment of pravastatin overdosage is recommended in the reviewed prescribing information. Management is supportive with monitoring for muscle and hepatic injury.
When should a nurse hold pravastatin?
Hold for suspected myopathy, dose above cyclosporine limit without clearance, gemfibrozil on the MAR, active liver disease, pregnancy, or new muscle symptoms with dark urine.
References
- U.S. National Library of Medicine. Pravastatin sodium tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c011348-a236-47d3-bbef-3e0b956dd080
- National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181).https://www.nice.org.uk/guidance/cg181
- American Heart Association. About cholesterol.https://www.heart.org/en/health-topics/cholesterol/about-cholesterol
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs
- U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.